Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

23.45 +0.26 (+1.12%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 612,087
Open 23.12
Bid (Size) 23.25 (1)
Ask (Size) 23.43 (1)
Prev. Close 23.19
Today's Range 22.89 - 23.51
52wk Range 14.47 - 26.16
Shares Outstanding 102,780,151
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Investors should take note of CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX), a growth stock that remains attractively priced.
CATALYST PHARMACEUTICALS INC was identified as an affordable growth stock. NASDAQ:CPRX is showing great growth, but also scores well on profitability. At the same time it seems to be priced... 
Via Chartmill
Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025
The Company will Host a Conference Call and Webcast on May 8, 2025, at 8:30 AM ET 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
+9.0%
+9.0%
1 Month
-6.8%
-6.8%
3 Month
+4.0%
+4.0%
6 Month
+9.3%
+9.3%
1 Year
+59.7%
+59.7%

More News

Read More
Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock.
Via Chartmill
Is CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) a Fit for high Growth Investing Strategies?
Via Chartmill
Earnings Scheduled For February 26, 2025
Via Benzinga
Why NASDAQ:CPRX qualifies as a high growth stock.
Via Chartmill
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a candidate for growth investors. Here's why.
Via Chartmill
Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Why Mark Minervini may look into CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)
Via Chartmill
Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday
Via The Motley Fool
Topics Economy Government World Trade
Exposures Economy Political Tariff
Why the growth investor may take a look at CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX).
Via Chartmill
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is showing decent growth, but is still valued reasonably.
Via Chartmill
Should you consider CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) for growth investing?
Via Chartmill
Celsius, Lucid And Signet Are Among Top 10 Mid-Cap Gainers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio?
Via Benzinga
For those who appreciate value investing, CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a compelling option with its solid fundamentals.
Via Chartmill
Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a CANSLIM stock.
Via Chartmill
Looking for growth without the hefty price tag? Consider CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX).
Via Chartmill
Is CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) on the Verge of a Major Breakout as a Strong Growth Stock?
Via Chartmill
Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Is CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) suited for growth investing?
Via Chartmill
Here's What's Driving Catalyst Pharmaceuticals Stock 8% Higher Today
Via The Motley Fool
Catalyst Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Via Benzinga
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via Chartmill
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Investors should take note of NASDAQ:CPRX, a growth stock that remains attractively priced.
Via Chartmill

Frequently Asked Questions

Is Catalyst Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Catalyst Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Catalyst Pharmaceuticals, Inc. - Common Stock trade on?
Catalyst Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Catalyst Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Catalyst Pharmaceuticals, Inc. - Common Stock is CPRX on the Nasdaq Stock Market
What is the current price of Catalyst Pharmaceuticals, Inc. - Common Stock?
The current price of Catalyst Pharmaceuticals, Inc. - Common Stock is 23.45
When was Catalyst Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Catalyst Pharmaceuticals, Inc. - Common Stock was at 04/25/25 04:00 PM ET
What is the market capitalization of Catalyst Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Catalyst Pharmaceuticals, Inc. - Common Stock is 2.41B
How many shares of Catalyst Pharmaceuticals, Inc. - Common Stock are outstanding?
Catalyst Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.